ASSESSMENT OF COGNITIVE AND BRAIN METABOLIC CHANGES IN RESPONSE TO IAS TREATMENT
评估 IAS 治疗引起的认知和脑代谢变化
基本信息
- 批准号:7603455
- 负责人:
- 金额:$ 0.12万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2007
- 资助国家:美国
- 起止时间:2007-04-01 至 2007-09-16
- 项目状态:已结题
- 来源:
- 关键词:Amyloid beta-ProteinAndrogen SuppressionAndrogensApolipoprotein EBehavioralBrainCognitionCognitiveComputer Retrieval of Information on Scientific Projects DatabaseDiagnosisFundingGrantInstitutionMalignant neoplasm of prostateMetabolicMetastatic Prostate CancerMethodsMoodsPhysiologicalProstate-Specific AntigenResearchResearch PersonnelResourcesSourceTestosteroneUnited States National Institutes of HealthWithdrawalbrain metabolismcancer diagnosiscognitive changemenresponsetreatment duration
项目摘要
This subproject is one of many research subprojects utilizing the
resources provided by a Center grant funded by NIH/NCRR. The subproject and
investigator (PI) may have received primary funding from another NIH source,
and thus could be represented in other CRISP entries. The institution listed is
for the Center, which is not necessarily the institution for the investigator.
Prostate cancer is the most common form of cancer diagnosed in men. Intermittent androgen suppression (IAS) is a common treatment strategy for men diagnosed with prostate cancer that cycles androgen withdrawal (6-9 months) with an "off treatment" period allowing testosterone levels to return to physiological levels. Treatment is then reinstated as the prostate specific antigen (PSA) reaches a threshold dependent upon primary therapy. The proposed study examines changes in mood, cognition, brain metabolism, and abeta levels in men with non-metastatic prostate cancer undergoing IAS treatment and healthy men, and will use both behavioral and brain metabolic methods to assess change. We will also examine APOE status as a possible modulating factor for cognitive changes
这个子项目是许多研究子项目中的一个
由NIH/NCRR资助的中心赠款提供的资源。子项目和
研究者(PI)可能从另一个NIH来源获得了主要资金,
因此可以在其他CRISP条目中表示。所列机构为
研究中心,而研究中心不一定是研究者所在的机构。
前列腺癌是男性最常见的癌症。间歇性雄激素抑制(IAS)是被诊断患有前列腺癌的男性的一种常见治疗策略,该策略以雄激素戒断(6-9个月)为周期,并有一段“停止治疗”期,使睾酮水平恢复到生理水平。 然后,当前列腺特异性抗原(PSA)达到依赖于主要治疗的阈值时,恢复治疗。 这项拟议的研究检查了接受IAS治疗的非转移性前列腺癌患者和健康男性的情绪,认知,脑代谢和abeta水平的变化,并将使用行为和脑代谢方法来评估变化。我们还将研究APOE状态作为认知变化的可能调节因素
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
MONIQUE CHERRIER其他文献
MONIQUE CHERRIER的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('MONIQUE CHERRIER', 18)}}的其他基金
Cognitive, Behavioral and Aging Effects of Opioids in Alcohol Users
阿片类药物对酒精使用者的认知、行为和衰老影响
- 批准号:
9476525 - 财政年份:2017
- 资助金额:
$ 0.12万 - 项目类别:
Cognitive, Behavioral and Aging Effects of Opioids in Alcohol Users
阿片类药物对酒精使用者的认知、行为和衰老影响
- 批准号:
8888498 - 财政年份:2015
- 资助金额:
$ 0.12万 - 项目类别:
Cognitive, Behavioral and Aging Effects of Opioids in Alcohol Users
阿片类药物对酒精使用者的认知、行为和衰老影响
- 批准号:
9110199 - 财政年份:2015
- 资助金额:
$ 0.12万 - 项目类别:
Assessment of Cognitive & Mood Effects from ADT in Men with Prostate Cancer
认知评估
- 批准号:
8082779 - 财政年份:2007
- 资助金额:
$ 0.12万 - 项目类别:
Assessment of Cognitive & Mood Effects from ADT in Men with Prostate Cancer
认知评估
- 批准号:
7320725 - 财政年份:2007
- 资助金额:
$ 0.12万 - 项目类别:
Assessment of Cognitive & Mood Effects from ADT in Men with Prostate Cancer
认知评估
- 批准号:
7630434 - 财政年份:2007
- 资助金额:
$ 0.12万 - 项目类别:
相似海外基金
Androgen Suppression Combined with Elective Nodal and a Dose Escalated Boost. A Non-Inferiority, Phase 3 Randomized Controlled Trial of Stereotactic Body Radiation Therapy versus Brachytherapy Boost (ASCENDE-SBRT)
雄激素抑制与选择性淋巴结和剂量递增相结合。
- 批准号:
463259 - 财政年份:2022
- 资助金额:
$ 0.12万 - 项目类别:
Operating Grants
A Randomized Phase II Trial of Flibanserin in Men Receiving Androgen Suppression for Prostate Cancer
氟班色林在接受雄激素抑制治疗前列腺癌的男性中的随机 II 期试验
- 批准号:
10195766 - 财政年份:2021
- 资助金额:
$ 0.12万 - 项目类别:
A Randomized Phase II Trial of Flibanserin in Men Receiving Androgen Suppression for Prostate Cancer
氟班色林在接受雄激素抑制治疗前列腺癌的男性中的随机 II 期试验
- 批准号:
10407479 - 财政年份:2021
- 资助金额:
$ 0.12万 - 项目类别:
SWOG 9343--ANDROGEN SUPPRESSION & FIXED SCHEDULE SURAMINE IN PROSTATE CANCER
SWOG 9343--雄激素抑制
- 批准号:
6253166 - 财政年份:1997
- 资助金额:
$ 0.12万 - 项目类别:
SWOG 9343--ANDROGEN SUPPRESSION & FIXED SCHEDULE SURAMINE IN PROSTATE CA
SWOG 9343--雄激素抑制
- 批准号:
5224996 - 财政年份:
- 资助金额:
$ 0.12万 - 项目类别:














{{item.name}}会员




